BILLS-117hr2891ih.pdf

2003 30 days year 2019 the preceding calendar year 6 2003 12-year 12-month December 31 1ST SESSION H. R. 2891 APRIL 28, 2021 15 U.S.C. 12(a year 2020 180-DAY later than 6 years 3-year 1112 21 PERIOD 1 year 42 U.S.C.

the ‘‘Preserve Access

PO 00000 Frm 00005 PO 00000 Frm 00001 PO 00000 Frm 00019 PO 00000 Frm 00013 PO 00000 Frm 00016 PO 00000 Frm 00017

the United States the District of Columbia Circuit United States New York the United States of America

IH Approved

sist

DSK79L0C42PROD ANDA NDA U.S.C. Commission SEC the Federal Trade uct the Federal Food, Drug the Public Health Service Act Federal Food, Drug Federal Trade Commission the Food and Drug Administration Senate NDA.—The GENERAL.—If the United States Court Medicare the Federal Food 14 Commission the Department of Justice the House of Representatives United States Patent and Trademark Office the Federal Trade Commission Legal Services the Public Health Service Congress Prescription Drug, Improvement Department of Labor Federal House of Representa- the Committee on Energy and Commerce FDA 360cc Drug, Improvement the Federal Trade Commis- the Committee on the Judiciary the Committee on the Judiciary of the Bureau of Labor Statistics

BUCK NADLER CAROLYN B. CICILLINE Act

biosimilar biological biosimilar biological product patent biological product generic prescription drug drug prescription delay proceeding entry claim biological products